Preparation Method of (DOTA)n-[Dendrimer PAMAM]- (Trastuzumab)m Conjugate as Radiopharmacutical Compound for Radioimmunotherapy of (177Lu-DOTA)n-[Dendrimer PAMAM]-(Trastuzumab)m

Authors

  • RIEN RITAWIDYA Pusat Radioisotop dan Radiofarmaka, Kawasan Puspiptek Serpong ,
  • SRI SETYOWATI Pusat Radioisotop dan Radiofarmaka, Kawasan Puspiptek Serpong ,
  • CECEP TAUFIK RUSTENDI Pusat Radioisotop dan Radiofarmaka, Kawasan Puspiptek Serpong ,
  • MASKUR MASKUR Pusat Radioisotop dan Radiofarmaka, Kawasan Puspiptek Serpong ,
  • MARTALENA RAMLI Pusat Radioisotop dan Radiofarmaka, Kawasan Puspiptek Serpong ,
  • BASUKI HIDAYAT UNIVERSITAS PADJAJARAN ,
  • MUHAMMAD SUBUR Pusat Radioisotop dan Radiofarmaka, Kawasan Puspiptek Serpong ,
  • ABDUL MUTALIB UNIVERSITAS PADJAJARAN ,
  • JOHAN MASHYUR UNIVERSITAS PADJAJARAN ,

Keywords:

0641/ff/13

Abstract

Radioimmunotherapy is one of modalities means of treatment for cancer that exploits the antibody monoclonal specificity to bind to its receptor and the ability of alfa or beta radiation in destroying cancer cells.  Trastuzumab is humanized IgG1 monoclonal antibodies which selectively bind to extracellular domain of Human Epidermal Growth Factor Receptor-2 (HER-2). HER-2 has now became a target receptor for treatment of human breast cancer due to their overexpression in the human breast cancer cell surface. This study was aimed in developing a method for preparation of  (DOTA) n-[Dendrimer PAMAM]-(trastuzumabm conjugate, a precursor of (177Lu-DOTA)n-PAMAM-(trastuzumab) m radioimmunoconjugate, which is expected to be  potential for breast cancer radioimmunotherapy. The conjugate was prepared through several conjugation steps. Characterization of (DOTA)n-[Dendrimer PAMAM]-(trastuzumab)m which was carried out by  using a HPLC equipped size exclusion column (SEC) gave a clean peak with retention time (tR) of 10.53 mins which was slower compared to tR of its precursor unconjugated trastuzumab (10.70 mins). This result indicated that molecular weight of (DOTA)n-[Dendrimer PAMAM]-(trastuzumab)m was bigger than its precursor (unconjugated trastuzumab) and pure. The purity of (DOTA)n-[Dendrimer PAMAM]-  (trastuzumab)m was verified by measuring the Rf of 177Lu-radiolabeled-(DOTA)n-[Dendrimer PAMAM]-(trastuzumab)m using instance thin layer chromatography-silica gel (ITLC-SG). The ITLC-SG of (DOTA)n-[Dendrimer PAMAM]-(trastuzumab)m which was radiolabeled with 177Lu- gave a clean peak with Rf of  <0.3, while the precursors which were regards as impurities, (free 177Lu in form 177Lu-EDTA, 177Lu-DOTA, and 177Lu- dendrimer PAMAM which was incubated as non specific binding), all of them gave Rf of >0.6. These ITLC results indicated that (DOTA)n-[Dendrimer PAMAM]-(trastuzumab)m radiolabeled with 177Lu was pure.

References

Downloads

Published

2014-09-30

Issue

Vol. 12 No. 2 (2014): JIFI

Section

Articles

License

Licencing
All articles in Jurnal Ilmu Kefarmasian Indonesia are an open-access article, distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License which permits unrestricted non-commercial used, distribution and reproduction in any medium.

This licence applies to Author(s) and Public Reader means that the users mays :

  • SHARE:
    copy and redistribute the article in any medium or format
  • ADAPT:
    remix, transform, and build upon the article (eg.: to produce a new research work and, possibly, a new publication)
  • ALIKE:
    If you remix, transform, or build upon the article, you must distribute your contributions under the same license as the original.
  • NO ADDITIONAL RESTRICTIONS:
    You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.

It does however mean that when you use it you must:

  • ATTRIBUTION: You must give appropriate credit to both the Author(s) and the journal, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.

You may not:

  • NONCOMMERCIAL: You may not use the article for commercial purposes.

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.